Glenmark Pharmaceuticals U.S. > News

News

Press Releases

Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.

Glenmark Pharmaceuticals Announces Top-Line Results from a Phase 3 Safety Study Evaluating Ryaltris™ in Patients with Perennial Allergic Rhinitis

December 13, 2017

Glenmark Pharmaceuticals Announces Dosing of First Patient With Investigational Immuno-Oncology Agent GBR 1342

December 7, 2017

Glenmark receives ANDA approval for HAILEY Fe 1-20

November 27, 2017

Glenmark Pharmaceuticals receives ANDA approval for HAILEY Fe 1-20

November 22, 2017

Glenmark receives ANDA approval for HAILEY 24 Fe

November 20, 2017

News

Search Result :-

Is an investigational new drug that has not been approved for commercial distribution in the United States.

December 13, 2017
Glenmark Pharmaceuticals Announces Top-Line Results from a Phase 3 Safety Study Evaluating Ryaltris™ in Patients with Perennial Allergic Rhinitis

December 7, 2017
Glenmark Pharmaceuticals Announces Dosing of First Patient With Investigational Immuno-Oncology Agent GBR 1342

November 27, 2017
Glenmark receives ANDA approval for HAILEY Fe 1-20

November 22, 2017
Glenmark Pharmaceuticals receives ANDA approval for HAILEY Fe 1-20

November 20, 2017
Glenmark receives ANDA approval for HAILEY 24 Fe

US Media Contact

For media inquiries only, please contact Corporate Communications.
uscomms@glenmarkpharma.com

Investor Relations

For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.

POTASSIUM CHLORIDE EXTENDED RELEASE CAPSULES 750mg RECALL REIMBURSEMENT POLICY

Over-the-counter (OTC)

ACCESSIBLE PRODUCTS

Who We Are

Injectables

OUR GROWING LINE